Inovio Pharmaceuticals (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "Inovio Pharmaceuticals" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
5th place
5th place
1,303rd place
2,228th place
234th place
190th place
low place
low place
low place
low place
2,393rd place
2,160th place
22nd place
60th place
low place
low place
low place
low place
airtable.com
- «COVID-19 vaccine tracker (Select vaccine tab)». Milken Institute. 22 de junho de 2020. Consultado em 23 de junho de 2020
bbc.com
- Mazumdar, Tulip (30 de janeiro de 2020). «Coronavirus: Scientists race to develop a vaccine». BBC News - Health. Consultado em 3 de fevereiro de 2020
clinicaltrialsarena.com
- «IVI and SNU partner to trial Inovio Covid-19 vaccine in Korea». Clinical Trials Arena. 5 de junho de 2020. Consultado em 8 de junho de 2020
doi.org
dx.doi.org
- Thanh Le. «The COVID-19 vaccine development landscape». Nature Reviews Drug Discovery. 19: 305–306. ISSN 1474-1776. PMID 32273591. doi:10.1038/d41573-020-00073-5
- Roybal. «Synthetic immunology: Hacking immune cells to expand their therapeutic capabilities». Annual Review of Immunology. 35: 229–253. ISSN 0732-0582. PMC 5555230
. PMID 28446063. doi:10.1146/annurev-immunol-051116-052302 - Modjarrad (2019). «Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial». The Lancet Infectious Diseases. 19: 1013–1022. ISSN 1473-3099. PMC 7185789. PMID 31351922. doi:10.1016/s1473-3099(19)30266-x
inovio.com
- «Proprietary smart devices (Cellectra)». Inovio Pharmaceuticals Inc. 2020. Consultado em 23 de junho de 2020
ivi.int
- «IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea». International Vaccine Institute. 16 de abril de 2020. Consultado em 23 de junho de 2020
- «IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea». International Vaccine Institute. 16 de abril de 2020. Consultado em 23 de abril de 2020
latimes.com
- Mike Freeman. «Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego». Los Angeles Times. Consultado em 17 de fevereiro de 2020
marketwatch.com
- Lee, Jaimy (23 de junho de 2020). «Inovio shares jump on government funding for vaccine device». MarketWatch. Consultado em 23 de junho de 2020
- Ciara Linnane (8 de março de 2020). «Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April». MarketWatch. Consultado em 8 de março de 2020
morethanthecurve.com
- «Plymouth Meeting's Inovio Pharmaceuticals granted $9 million to develop a vaccine for current coronavirus in China». More Than The Curve. Consultado em 17 de fevereiro de 2020
nature.com
- Thanh Le. «The COVID-19 vaccine development landscape». Nature Reviews Drug Discovery. 19: 305–306. ISSN 1474-1776. PMID 32273591. doi:10.1038/d41573-020-00073-5
nih.gov
ncbi.nlm.nih.gov
- Thanh Le. «The COVID-19 vaccine development landscape». Nature Reviews Drug Discovery. 19: 305–306. ISSN 1474-1776. PMID 32273591. doi:10.1038/d41573-020-00073-5
- Roybal. «Synthetic immunology: Hacking immune cells to expand their therapeutic capabilities». Annual Review of Immunology. 35: 229–253. ISSN 0732-0582. PMC 5555230. PMID 28446063. doi:10.1146/annurev-immunol-051116-052302
- Modjarrad (2019). «Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial». The Lancet Infectious Diseases. 19: 1013–1022. ISSN 1473-3099. PMC 7185789. PMID 31351922. doi:10.1016/s1473-3099(19)30266-x
thelancet.com
- Modjarrad (2019). «Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial». The Lancet Infectious Diseases. 19: 1013–1022. ISSN 1473-3099. PMC 7185789. PMID 31351922. doi:10.1016/s1473-3099(19)30266-x
worldcat.org
- Thanh Le. «The COVID-19 vaccine development landscape». Nature Reviews Drug Discovery. 19: 305–306. ISSN 1474-1776. PMID 32273591. doi:10.1038/d41573-020-00073-5
- Roybal. «Synthetic immunology: Hacking immune cells to expand their therapeutic capabilities». Annual Review of Immunology. 35: 229–253. ISSN 0732-0582. PMC 5555230. PMID 28446063. doi:10.1146/annurev-immunol-051116-052302
- Modjarrad (2019). «Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial». The Lancet Infectious Diseases. 19: 1013–1022. ISSN 1473-3099. PMC 7185789. PMID 31351922. doi:10.1016/s1473-3099(19)30266-x